Medidata Solutions
announced that specialty contract research organization (CRO) QCTR Ltd. has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.
Scotland-based QCTR was founded in 2006 to fill an ndustry need for CRO expertise in central nervous system (CNS) clinical research. As their study pipeline grew, QCTR realized that a commercial trial management solution was necessary to efficiently do more with existing resource.
“Compared to other available systems, Medidata’s SaaS-based CTMS solution offered much greater value in terms of richness of features, speed of set-up, flexibility, ease-of-use and global accessibility—without requiring extensive up-front investment,” said Susan McGoldrick, Managing Director, QCTR. “It’s evident that Medidata CTMS was developed with CRO-specific needs in mind. We’re especially excited about the opportunities to more proactively manage the performance of investigator sites and streamline how we pay them—key aspects in our strategy to maintain our sites’ high satisfaction and patient recruitment excellence as we scale our business.”
QCTR anticipates that Medidata CTMS will greatly reduce the time and effort needed to track key milestones and operational metrics across their clinical studies and sites—both from the perspective of data entry as well as timely access to information and reports. As a result, study managers and monitors should be able to maintain a tight handle on issues despite increased study volumes and quickly follow up with sites.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.